Revance Therapeutics, Inc. (Revance) today announced a settlement and
termination agreement for its contractual relationships with Medicis
Pharmaceutical Corporation MRX concerning RT001 Botulinum Toxin Type A
Topical Gel and RT002 Injectable Botulinum Toxin Type A. As part of the
settlement, all worldwide rights to develop and commercialize both products
across all indications will be returned to Revance. The agreement will also
resolve the outstanding litigation between the companies.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in